Literature DB >> 29251796

Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation.

Chun-Seok Cho1, Hwan-Woo Park1,2, Allison Ho1, Ian A Semple1, Boyoung Kim1, Insook Jang1, Haeli Park1, Shannon Reilly1,3,4, Alan R Saltiel1,3,4, Jun Hee Lee1.   

Abstract

Obesity commonly leads to hepatic steatosis, which often provokes lipotoxic injuries to hepatocytes that cause nonalcoholic steatohepatitis (NASH). NASH, in turn, is associated with the accumulation of insoluble protein aggregates that are composed of ubiquitinated proteins and ubiquitin adaptor p62/sequestosome 1 (SQSTM1). Formation of p62 inclusions in hepatocytes is the critical marker that distinguishes simple fatty liver from NASH and predicts a poor prognostic outcome for subsequent liver carcinogenesis. However, the molecular mechanism by which lipotoxicity induces protein aggregation is currently unknown. Here, we show that, upon saturated fatty acid-induced lipotoxicity, TANK binding kinase 1 (TBK1) is activated and phosphorylates p62. TBK1-mediated p62 phosphorylation is important for lipotoxicity-induced aggregation of ubiquitinated proteins and formation of large protein inclusions in hepatocytes. In addition, cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING), upstream regulators of TBK1, are involved in lipotoxic activation of TBK1 and subsequent p62 phosphorylation in hepatocytes. Furthermore, TBK1 inhibition prevented formation of ubiquitin-p62 aggregates not only in cultured hepatocytes, but also in mouse models of obesity and NASH.
CONCLUSION: These results suggest that lipotoxic activation of TBK1 and subsequent p62 phosphorylation are critical steps in the NASH pathology of protein inclusion accumulation in hepatocytes. This mechanism can provide an explanation for how hypernutrition and obesity promote the development of severe liver pathologies, such as steatohepatitis and liver cancer, by facilitating the formation of p62 inclusions. (Hepatology 2018).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29251796      PMCID: PMC6005718          DOI: 10.1002/hep.29742

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  Hepatocellular ballooning in NASH.

Authors:  Stephen Caldwell; Yoshihiro Ikura; Daniela Dias; Kosuke Isomoto; Akito Yabu; Christopher Moskaluk; Patcharin Pramoonjago; Winsor Simmons; Harriet Scruggs; Nicholas Rosenbaum; Timothy Wilkinson; Patsy Toms; Curtis K Argo; Abdullah M S Al-Osaimi; Jan A Redick
Journal:  J Hepatol       Date:  2010-06-25       Impact factor: 25.083

Review 2.  Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.

Authors:  Andrea Marengo; Chiara Rosso; Elisabetta Bugianesi
Journal:  Annu Rev Med       Date:  2015-10-14       Impact factor: 13.739

Review 3.  Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.

Authors:  Kenneth Cusi
Journal:  Gastroenterology       Date:  2012-02-08       Impact factor: 22.682

Review 4.  Calcium channel blockers as potential therapeutics for obesity-associated autophagy defects and fatty liver pathologies.

Authors:  Hwan-Woo Park; Jun Hee Lee
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

Review 5.  Broad spectrum of hepatocyte inclusions in humans, animals, and experimental models.

Authors:  Pavel Strnad; Renwar Nuraldeen; Nurdan Guldiken; Daniel Hartmann; Vineet Mahajan; Helmut Denk; Johannes Haybaeck
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

Review 6.  The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling.

Authors:  Suneng Fu; Steven M Watkins; Gökhan S Hotamisligil
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

Review 7.  STING-dependent cytosolic DNA sensing pathways.

Authors:  Glen N Barber
Journal:  Trends Immunol       Date:  2013-12-02       Impact factor: 16.687

8.  Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.

Authors:  Kristopher Clark; Lorna Plater; Mark Peggie; Philip Cohen
Journal:  J Biol Chem       Date:  2009-03-22       Impact factor: 5.157

9.  A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis.

Authors:  Shannon M Reilly; Maryam Ahmadian; Brian F Zamarron; Louise Chang; Maeran Uhm; BreAnne Poirier; Xiaoling Peng; Danielle M Krause; Evgenia Korytnaya; Adam Neidert; Christopher Liddle; Ruth T Yu; Carey N Lumeng; Elif A Oral; Michael Downes; Ronald M Evans; Alan R Saltiel
Journal:  Nat Commun       Date:  2015-01-12       Impact factor: 14.919

10.  An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.

Authors:  Masahiko Matsumoto; Natsuko Hada; Yoshiyuki Sakamaki; Akiko Uno; Toshihiko Shiga; Chiaki Tanaka; Tsuneo Ito; Asao Katsume; Masayuki Sudoh
Journal:  Int J Exp Pathol       Date:  2013-01-11       Impact factor: 1.925

View more
  27 in total

1.  Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice.

Authors:  Xianjun Luo; Honggui Li; Linqiang Ma; Jing Zhou; Xin Guo; Shih-Lung Woo; Ya Pei; Linda R Knight; Michael Deveau; Yanming Chen; Xiaoxian Qian; Xiaoqiu Xiao; Qifu Li; Xiangbai Chen; Yuqing Huo; Kelly McDaniel; Heather Francis; Shannon Glaser; Fanyin Meng; Gianfranco Alpini; Chaodong Wu
Journal:  Gastroenterology       Date:  2018-09-10       Impact factor: 22.682

2.  STING-mediated inflammation in Kupffer cells contributes to progression of nonalcoholic steatohepatitis.

Authors:  Yongsheng Yu; Yu Liu; Weishuai An; Jingwen Song; Yuefan Zhang; Xianxian Zhao
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

3.  Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy.

Authors:  Kunpeng Liu; Dongbo Qiu; Xue Liang; Yingqi Huang; Yao Wang; Xin Jia; Kun Li; Jingyuan Zhao; Cong Du; Xiusheng Qiu; Jun Cui; Zhendong Xiao; Yunfei Qin; Qi Zhang
Journal:  Autophagy       Date:  2021-08-12       Impact factor: 13.391

4.  Glutamate-oxaloacetate transaminase activity promotes palmitate lipotoxicity in rat hepatocytes by enhancing anaplerosis and citric acid cycle flux.

Authors:  Robert A Egnatchik; Alexandra K Leamy; Sarah A Sacco; Yi Ern Cheah; Masakazu Shiota; Jamey D Young
Journal:  J Biol Chem       Date:  2018-12-18       Impact factor: 5.157

5.  Lipotoxicity reduces DDX58/Rig-1 expression and activity leading to impaired autophagy and cell death.

Authors:  Karla K Frietze; Alyssa M Brown; Dividutta Das; Raymond G Franks; Jessie Lee Cunningham; Michael Hayward; Joseph T Nickels
Journal:  Autophagy       Date:  2021-05-09       Impact factor: 16.016

Review 6.  The cGAS-STING Pathway: Novel Perspectives in Liver Diseases.

Authors:  Dongwei Xu; Yizhu Tian; Qiang Xia; Bibo Ke
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 8.786

Review 7.  The STING1 network regulates autophagy and cell death.

Authors:  Ruoxi Zhang; Rui Kang; Daolin Tang
Journal:  Signal Transduct Target Ther       Date:  2021-06-02

Review 8.  STING and liver disease.

Authors:  Can Chen; Rui-Xia Yang; Hua-Guo Xu
Journal:  J Gastroenterol       Date:  2021-06-23       Impact factor: 7.527

9.  FIP200 controls the TBK1 activation threshold at SQSTM1/p62-positive condensates.

Authors:  David Schlütermann; Niklas Berleth; Jana Deitersen; Nora Wallot-Hieke; Olena Friesen; Wenxian Wu; Fabian Stuhldreier; Yadong Sun; Lena Berning; Annabelle Friedrich; María José Mendiburo; Christoph Peter; Constanze Wiek; Helmut Hanenberg; Anja Stefanski; Kai Stühler; Björn Stork
Journal:  Sci Rep       Date:  2021-07-05       Impact factor: 4.379

10.  Holistic characterization of single-hepatocyte transcriptome responses to high-fat diet.

Authors:  Sung Rye Park; Chun-Seok Cho; Jingyue Xi; Hyun Min Kang; Jun Hee Lee
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-10-26       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.